Gain Therapeutics Files 8-K: Details Pending
Ticker: GANX · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, other-events
TL;DR
Gain Therapeutics filed an 8-K, but no one knows why yet.
AI Summary
Gain Therapeutics, Inc. filed an 8-K on October 6, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates a material event has occurred for Gain Therapeutics, but the lack of specific information leaves investors uncertain about the company's current situation.
Risk Assessment
Risk Level: medium — The filing of an 8-K signals a significant event, but the absence of details creates uncertainty and potential risk for investors.
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- 001-40237 (company) — SEC File Number
- 85-1726310 (company) — IRS Employer Identification No.
- October 6, 2025 (date) — Filing Date
FAQ
What specific event(s) are being reported in this 8-K filing?
The filing is categorized under 'Other Events' but does not provide specific details regarding the nature of the event(s) reported.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on October 6, 2025.
What is the principal executive office address for Gain Therapeutics, Inc.?
The address is 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.
What is the telephone number for Gain Therapeutics, Inc.?
The telephone number is (301) 500-1556.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 609 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2025-10-06 17:01:14
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 GANX The Nasdaq Stock Market LLC It
Filing Documents
- tm2528094d1_8k.htm (8-K) — 25KB
- 0001104659-25-097153.txt ( ) — 189KB
- ganx-20251006.xsd (EX-101.SCH) — 3KB
- ganx-20251006_lab.xml (EX-101.LAB) — 33KB
- ganx-20251006_pre.xml (EX-101.PRE) — 22KB
- tm2528094d1_8k_htm.xml (XML) — 4KB
01 Other Information
Item 8.01 Other Information On October 6, 2025, Gain Therapeutics, Inc. (the "Company") presented preliminary data from the Company's ongoing Phase 1b clinical study of GT-02287 in people with Parkinson's disease ("PD") with or without a GBA1 mutation at the International Congress of Parkinson's Disease and Movement Disorders. Preliminary Findings After 90 days of dosing, GT-02287 has been safe and generally well tolerated, with no treatment-emergent serious adverse events observed. A transient increase in alkaline phosphatase and other liver enzymes has been observed in some participants and normalized despite ongoing dosing. Of the 21 study participants, two are treatment-nave, two are on deep brain stimulation, and 18 are on levodopa and/or dopamine agonists or other PD drugs. Mean MDS-UPDRS scores at baseline were 5.8, 7.4, and 24.7 for Parts I, II, and III, respectively. Several participants experienced an improvement in their UPDRS Part II and III scores after 90 days of dosing with GT-02287 while mean Part I scores remained unchanged. The mean improvement in Parts II and III by Day 90, which was not observed by Day 30, suggests that GT-02287 has a disease-slowing effect, consistent with the preclinical models in vivo and the proposed mechanism of action of GT-02287, supporting continued development. The plasma pharmacokinetics (PK) profile was consistent across all 14 participants sampled, was within the projected therapeutics range, and comparable to exposures observed in healthy volunteers in the Phase 1 study. At two different meetings, the data monitoring committee has recommended continuation of the study and more recently, Australian health authorities have approved the Phase 1b study extension for patients who can now be treated for up to 12 months. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. G